CAMBRIDGE, Mass., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that CEO and Founder Nessan Bermingham, Ph.D., will present at the 2016 Wedbush PacGrow Healthcare Conference.
Details of the presentation are as follows:
2016 Wedbush PacGrow Healthcare Conference
Date: Wednesday, August 17th
Location: Le Parker Meridien, New York
Presentation Time: 10:55 AM EST
Individuals may access a live webcast of the presentation on the Intellia website at www.intelliatx.com under "Upcoming Events" in the "Events & Presentations" section. A replay of the webcast will be available on this site for 90 days following the live event.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia was named as one of the top 10 biotech start-ups by Nature Biotechnology. In September 2015, Intellia was named a “Fierce 15” biotech company by FierceBiotech. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact: Jennifer Mound Smoter Chief External Affairs & Communications Officer +1 224-804-4462 firstname.lastname@example.org Investor Contacts: John Graziano Trout Group +1 646-378-2942 email@example.com Chad Rubin Trout Group +1 646-378-2947 firstname.lastname@example.org
Source:Intellia Therapeutics, Inc.